Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. by Travis, R, Spencer, E, Allen, N, Appleby, P, Roddam, A, Overvad, K, Johnsen, N, Olsen, A, Kaaks, R, Linseisen, J, Boeing, H, Nöthlings, U, Bueno-de-Mesquita, H, Ros, M, Sacerdote, C, Palli, D, Tumino, R, Berrino, F, Trichopoulou, A, Dilis, V, Trichopoulos, D, Chirlaque, MD, Ardanaz, E, Larranaga, N, Gonzalez, C

“…There was no evidence of heterogeneity in these results by age at blood collection or country of recruitment, nor by cancer stage or grade. These results suggest that higher concentrations of circulating genistein may reduce the risk of prostate cancer but do not support an association with plasma lignans.…”

Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). by Travis, R, Crowe, F, Allen, N, Appleby, P, Roddam, A, Tjønneland, A, Olsen, A, Linseisen, J, Kaaks, R, Boeing, H, Kröger, J, Trichopoulou, A, Dilis, V, Trichopoulos, D, Vineis, P, Palli, D, Tumino, R, Sieri, S, Bueno-de-Mesquita, H, van Duijnhoven, F, Chirlaque, MD, Barricarte, A, Larrañaga, N, González, C, Argüelles, M, Sánchez, M, Stattin, P, Hallmans, G, Khaw, K, Bingham, S, Rinaldi, S, Slimani, N, Jenab, M, Riboli, E, Key, T

“…Subgroup analyses showed no significant heterogeneity by cancer stage or grade, age at diagnosis, body mass index, time from blood collection to diagnosis, or calcium intake. …”

Serum vitamin d and risk of prostate cancer in a case-control analysis nested within the european prospective investigation into cancer and nutrition (EPIC) by Travis, R, Crowe, F, Allen, N, Appleby, P, Roddam, A, Tjønneland, A, Olsen, A, Linseisen, J, Kaaks, R, Boeing, H, Kröger, J, Trichopoulou, A, Dilis, V, Trichopoulos, D, Vineis, P, Palli, D, Tumino, R, Sieri, S, Bueno-De-Mesquita, H, Van Duijnhoven, F, Chirlaque, M, Barricarte, A, Larrañaga, N, González, C, Argüelles, M

“…Subgroup analyses showed no significant heterogeneity by cancer stage or grade, age at diagnosis, body mass index, time from blood collection to diagnosis, or calcium intake. …”